Pfizer (PFE) : Evanston Investments Dba Evanston Advisors scooped up 5,131 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 195,908 shares of Pfizer which is valued at $6,578,591.Pfizer makes up approximately 2.22% of Evanston Investments Dba Evanston Advisors’s portfolio.
Pfizer opened for trading at $33.38 and hit $33.59 on the upside on Friday, eventually ending the session at $33.58, with a gain of 0.03% or 0.01 points. The heightened volatility saw the trading volume jump to 2,31,70,974 shares. Company has a market cap of $207,663 M.
Other Hedge Funds, Including , Mcrae Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 1,354 additional shares and now holds a total of 10,743 shares of Pfizer which is valued at $360,750. Pfizer makes up approx 0.16% of Mcrae Capital Management Inc’s portfolio.Boston Family Office boosted its stake in PFE in the latest quarter, The investment management firm added 17,488 additional shares and now holds a total of 149,871 shares of Pfizer which is valued at $4,902,280. Pfizer makes up approx 0.65% of Boston Family Office’s portfolio.Farmers Trust Co reduced its stake in PFE by selling 1,633 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 157,715 shares of PFE which is valued at $5,247,178. Pfizer makes up approx 1.67% of Farmers Trust Co’s portfolio.Beech Hill Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 2,594 additional shares and now holds a total of 165,719 shares of Pfizer which is valued at $5,513,471. Pfizer makes up approx 4.27% of Beech Hill Advisors’s portfolio.Umb Bank N Amo reduced its stake in PFE by selling 41,399 shares or 6.29% in the most recent quarter. The Hedge Fund company now holds 616,540 shares of PFE which is valued at $20,512,286. Pfizer makes up approx 0.86% of Umb Bank N Amo’s portfolio.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Pfizer. Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.